Girl receiving an injection in her upper arm.

Vaccines and immunization

Lifesaving vaccines for every child

Opportunity

Reach every child around the world with vaccines to prevent diseases that now kill 1.5 million children every year.

Innovations

Vaccines and vaccine technologies developed by PATH and our partners have reached billions of people worldwide. We work on early discovery, testing, regulatory issues, manufacturing, and vaccine introduction and delivery to protect against 15 different diseases. Our work has contributed to a more than 50 percent reduction in child mortality over the past three decades.

Health workers preparing syringes of vaccine.
PATH accelerated the delivery of a vaccine against deadly Japanese encephalitis in Laos and Cambodia, and our vaccine technologies helped ensure the vaccine’s safe arrival in each community.

2015 impact

  • The MenAfriVac® vaccine has reached more than 235 million Africans, leading to the disappearance of meningitis A epidemics in Africa wherever the vaccine has been introduced. The vaccine was developed through a partnership among PATH, the World Health Organization, and Serum Institute of India Pvt. Ltd. Preparations are under way to include the vaccine as part of routine national immunization programs. A PATH-supported vaccine candidate against other causes of epidemic meningitis in Africa is ready to enter clinical trials in 2016.

  • PATH also helped expand access to MenAfriVac through an innovative approach that allows transport and distribution of the vaccine in remote areas without ice or refrigeration.

  • Laos launched a nationwide immunization campaign to protect 1.5 million children against Japanese encephalitis (JE), an incurable and deadly disease. Cambodia followed suit in 2016. For more than a decade, we worked with partners to identify and accelerate the delivery of an affordable JE vaccine and support country-led efforts that have reached more than 232 million children across Southeast Asia to date.

  • PATH and our partners advanced clinical trials of seven vaccine candidates to protect against the two top killers of children—pneumonia and diarrheal disease.

  • We redoubled our commitment to reach every child with lifesaving vaccines by launching the new Center for Vaccine Innovation and Access. The center brings together PATH’s vaccine experts into a single team working across every stage of the long, complex process of vaccine research, development, and introduction.

MenAfriVac is a registered trademark of Serum Institute of India Pvt. Ltd.